Author

Hideki Toyosaki

Observed name: H Toyosaki

Institution: Eisai (United States)

Observed institution: Eisai (United States)

OpenAlex ID: A5117430540

Characterizing the Journey of Early Alzheimer’s Disease in Patients Initiating Lecanemab Treatment in the United States: A Real-World Evidence Study

2025 · Marwan N. Sabbagh, Chenyue Zhao, et al. · Neurology and Therapy · 12

Initial Real-World Evidence for Lecanemab in the United States

2025 · Diana I. Brixner, Chenyue Zhao, et al. · Drugs & Aging · 3

Early Alzheimer's disease patient care pathway and health system readiness: A framework for integrated care

2025 · Ilya M. Nasrallah, Cate Polacek, et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 2

Operational Consideration and Best Practices for Implementation of an Early Alzheimer's Disease Patient Care Pathway

2025 · Babak Tousi, Feride H Frech, et al. · Alzheimer s & Dementia

Understanding real‐world clinical experience with lecanemab: Capturing the patient and care partner voice through social media listening

2025 · Monica K Crane, Lee Watson, et al. · Alzheimer s & Dementia

Patient and care partner expectations and emotional experiences of lecanemab: A social media listening study

2025 · Monica K Crane, Lee Watson, et al. · Alzheimer s & Dementia

Observational Study Evaluating Blood‐Based Biomarker Use for Confirmatory Alzheimer's Disease Diagnosis in Real‐World Clinical Practice Within the United States

2025 · Marwan N. Sabbagh, Daryl Jones, et al. · Alzheimer s & Dementia

Implementation Science Study Evaluating the Real‐World Use of Blood‐Based Biomarkers as Confirmatory Diagnostic Tools for Alzheimer's Disease in the United States

2025 · Daryl Jones, Jo Vandercappellen, et al. · Alzheimer s & Dementia

P.005 Real-world evidence of Lecanemab use in the United Statese

2025 · C Zhao, DI Brixner, et al. · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques

Works count: 9

Citation count: 17

H-index: 2

I10-index: 1